AstraZeneca Awards $3.4M for US Access, Citi Upholds £170 Target Citing Top Pipeline
AstraZeneca is allocating $3.4 million to US healthcare access programs aimed at improving patient reach nationwide. Citi has reiterated a buy rating with a £170 target, citing a sector-leading pipeline and projecting low double-digit earnings growth alongside medium single- to high single-digit revenue growth in 2026.
1. Healthcare Access Funding
AstraZeneca has committed $3.4 million to programs designed to improve access to healthcare for patients across the United States. The funding will support initiatives that address barriers to care, enhance community outreach and strengthen partnerships with local health providers.
2. Citi Maintains Buy Rating
Citi has maintained its buy recommendation on AstraZeneca with an unchanged price target of £170, highlighting the company’s sector-leading clinical pipeline. The bank forecasts low double-digit earnings growth in 2026 and medium single- to high single-digit revenue growth, driven by strong trial momentum and upcoming product launches.